- Home
- / Edwards Lifesciences
- / Revenue
Edwards LifesciencesAnnual Revenue ($)
Edwards Lifesciences revenue was $4.39 b in FY, 2020
Quarterly Revenue ($)
Annual Growth Rate (%)
Revenue Breakdown
Business Segment
Geographic Segment
Edwards Lifesciences revenue breakdown by business segment: 17.0% from Critical Care, 19.4% from Surgical Structural Heart, 63.0% from Transcatheter Aortic Valve Replacement and 0.6% from Other
Edwards Lifesciences revenue breakdown by geographic segment: 21.6% from Europe, 9.9% from Rest of World, 10.2% from Japan and 58.2% from United States
| FY, 2019 | FY, 2017 | FY, 2018 | |
|---|---|---|---|
| Surgical Heart Valve Therapy | $807.1 m | $761.6 m | |
| Transcatheter Heart Valve Therapy | $2.03 b | $2.29 b | |
| Critical Care | $740.2 m | $601 m | $674.5 m |
| Surgical Structural Heart | $841.7 m | ||
| Transcatheter Mitral and Tricuspid Therapies | $28.2 m | ||
| Transcatheter Aortic Valve Replacement | $2.74 b |
| FY, 2019 | FY, 2017 | FY, 2018 | |
|---|---|---|---|
| Europe | $941.2 m | $831 m | $885.1 m |
| Rest of World | $429.4 m | $346.4 m | $385.6 m |
| Japan | $444.7 m | $350.3 m | $396.8 m |
| United States | $2.53 b | $1.91 b | $2.06 b |
Need Data?
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.